A new vaccine for glioblastoma brain cancer suspends tumor growth and is well tolerated by patients, according to the results of an early phase clinical trial.
Combining carboplatin, a common chemotherapy drug, with everolimus, a drug that blocks mTOR, is effective at inducing apoptosis and slowing tumor growth in patients with pediatric low-grade glioma brain cancer.
Researchers have developed a new approach that uses microRNA in combination with chemotherapy to help treat glioblastoma brain cancer. In preclinical models, the approach increases survival of the deadly brain cancer five fold.
Researchers report our gender can determine longevity and response to treatment for glioblastoma brain cancer. The study reports male survival is determined by genes that control cell division, where as female survival is often determine by genes that regulate the ability of cancer cells to migrate to different brain areas.
A new study reveals how the physical force exerted by the solid components of brain tumors impacts surrounding tissue, resulting in apoptosis and neurological dysfunction. Researchers reports the drug lithium, commonly prescribed for bipolar disorder, can help reverse some of the damage caused by the solid stress of the tumor.
A new study reports bigger brain size could mean an increased risk of developing brain cancer. The reason, researchers say, is simple. Bigger brains have more brain cells, and thus a greater potential for cell mutations that lead to cancer.
Using an open source platform called The Virtual Brain, researchers have simulated neural activity based on individual patient brain tumors.
A newly developed model that mimics the blood-brain barrier could help researchers more efficiently test drugs to treat a range of neurological diseases.
Researchers discover key elements associated with tumor cells binding to blood vessels. The findings could help develop new treatments to halt the development of brain tumors.
Researchers from the University of Plymouth have discovered the tole PrPC plays in the development of neurofibromatosis 2 tumors. According to the study, the prion protein is overproduced in schwannomas, compared with healthy Schwann cells. This overproduction is a result of Merlin deficiency and contributed to tumor growth in NF2 patients.
A new study reports on the benefits of precision medicine for treating pediatric brain cancer.
Researchers believe their findings could lead to new targets for brain cancer therapies.
